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OBJECTIVE—Autophagy is a critical cellular system for re-
moval of aggregated proteins and damaged organelles. Although
dysregulated autophagy is implicated in the development of heart
failure, the role of autophagy in the development of diabetic
cardiomyopathy has not been studied. We investigated whether
chronic activation of the AMP-activated protein kinase (AMPK) by
metformin restores cardiac function and cardiomyocyte autophagy
in OVE26 diabetic mice.
RESEARCH DESIGN AND METHODS—OVE26 mice and
cardiac-speciﬁc AMPK dominant negative transgenic (DN)-AMPK
diabetic mice were treated with metformin or vehicle for 4
months, and cardiac autophagy, cardiac functions, and cardio-
myocyte apoptosis were monitored.
RESULTS—Compared with control mice, diabetic OVE26 mice
exhibited a signiﬁcant reduction of AMPK activity in parallel with
reduced cardiomyocyte autophagy and cardiac dysfunction in vivo
and in isolated hearts. Furthermore, diabetic OVE26 mouse hearts
exhibited aggregation of chaotically distributed mitochondria
between poorly organized myoﬁbrils and increased polyubiquiti-
nated protein and apoptosis. Inhibition of AMPK by overexpres-
sion of a cardiac-speciﬁc DN-AMPK gene reduced cardiomyocyte
autophagy, exacerbated cardiac dysfunctions, and increased mor-
tality in diabetic mice. Finally, chronic metformin therapy
signiﬁcantly enhanced autophagic activity and preserved cardiac
functions in diabetic OVE26 mice but not in DN-AMPK diabetic
mice.
CONCLUSIONS—Decreased AMPK activity and subsequent
reduction in cardiac autophagy are important events in the
development of diabetic cardiomyopathy. Chronic AMPK activa-
tion by metformin prevents cardiomyopathy by upregulating
autophagy activity in diabetic OVE26 mice. Thus, stimulation of
AMPK may represent a novel approach to treat diabetic cardio-
myopathy. Diabetes 60:1770–1778, 2011
A
utophagy is a physiologic process whereby cy-
toplasmic components, including long-lived
proteins and organelles, are engulfed by a
double-membrane structure and targeted for
destruction in lysosomes (1). It selectively removes dam-
aged mitochondria as a cytoprotective mechanism for
limiting mitochondria-derived oxidative stress and prevent-
ing apoptosis (2,3). A low level of constitutive autophagy is
important in the heart for maintaining normal cellular
function and the quality of proteins and organelles. Defects
in this process cause cardiac dysfunction and heart failure,
particularly when cellular stress is increased (4). Although
autophagy is implicated in various pathologic conditions,
including cardiac hypertrophy, cardiomyopathy, and heart
failure, there is little information on the pathophysiologic
roles of autophagy in the pathogenesis of diabetic cardio-
myopathy.
Metformin, one of the most commonly prescribed anti-
diabetic drugs, improves cardiac function and reduces the
incidence of myocardial infarction in type 2 diabetic
patients (5,6). The UK Prospective Diabetes Study reported
that metformin was more effective than sulfonylureas
or insulin in reducing all-cause mortality and diabetes-
related end points in diabetic patients, even though these
agents decreased HbA1c by comparable magnitudes. These
ﬁndings suggest that metformin provides cardiovascular
protection independent of its hypoglycemic effects (7).
Indeed, metformin ameliorates cardiac dysfunctions in-
duced by global ischemia, without affecting blood glucose
in nondiabetic animals (8,9), by activating the AMP-
activated protein kinase (AMPK) (10,11). AMPK acts as
a sensor of cellular energy status and controls several
cellular functions in the cardiovascular system, including
protein synthesis (12,13), apoptosis (14–16), and auto-
phagy (17,18) in physiologic and pathologic conditions,
such as hemodynamic stress (12,13), myocardial ischemia,
and reperfusion injury (16,19,20). However, the roles and
molecular mechanisms by which AMPK regulates diabetic
cardiomyopathy remain to be established.
Diabetic cardiomyopathy, which develops in diabetic
patients in the absence of coronary artery disease or hy-
pertension (21–24), is a major cause of heart failure in di-
abetic patients. It is characterized by reduced cardiomyocyte
contractility, cardiac apoptosis, mitochondrial pathology,
and dysfunction (25,26). Despite the importance of this
complication, the underlying mechanisms of diabetic car-
diomyopathy are still poorly understood. Thus, this study
was designed to test whether decreased autophagy is
associated with the development of cardiomyopathy in
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ORIGINAL ARTICLEdiabetic OVE26 mice and to evaluate whether metformin
improves cardiac function by modulating autophagic ac-
tivity in diabetes.
RESEARCH DESIGN AND METHODS
Animals. Male OVE26 mice on a Friend virus B (FVB) background and control
FVB mice purchased from Jackson Laboratory (Bar Harbor, ME) were used for
the experiment at 6 months of age. To study the role of AMPK, one group of
OVE26 mice was treated with metformin (200 mg/kg per day, in drinking water)
for 4 months. In addition, cardiac-speciﬁc transgenic mice overexpressing
a dominant negative (DN) a2 subunit (D157A) of AMPK (DN-AMPKa2, a gift of
Rong Tian, University of Washington, Seattle, WA), aged 8 weeks old, were
rendered diabetic by ﬁve consecutive daily injections of streptozotocin (STZ,
50 mg/kg i.p.), whereas control mice were injected with vehicle (citrate buffer,
pH 4.5). In separate groups of wild-type (WT) diabetic and DN-AMPKa2d i -
abetic mice, metformin was administrated in drinking water (200 mg/kg per
day) for 4 months.
HbA1c was measured by a commercial cartridge, using the principle of
column chromatography, manufactured by Cholestech GDX A1C System (Bio-
Rad Laboratories, Hertfordshire, U.K.). Blood glucose and arterial blood
pressure were measured as described previously (27,28). Mice with blood
glucose .350 mg/dL were considered diabetic. All animal protocols were
reviewed and approved by the University of Oklahoma Institute Animal Care
and Use Committee.
Materials. The S-adenosylmethionine peptide was purchased from Upstate
Biotechnology, Inc. (Lake Placid, NY). Antibodies against phospho-AMPK
(Thr172), AMPK-a, phospho-mammalian target of rapamycin (mTOR; Ser2448),
mTOR, phospho-Raptor (Ser792), Raptor, phospho-4E-BP1 (Thr37/46), phospho-
p70 S6 kinase (Thr389), S6K, LC3, Beclin1, and ubiquitin were purchased
from Cell Signaling (Danvers, MA). Antibodies against phospho-mTOR
(Thr2446) and phospho-Raptor (Ser722) were from Millipore (Billerica,
MA). Anti-Raptor antibody was purchased form Abcam (Cambridge, MA). All
other chemicals and organic solvents were obtained from Sigma-Aldrich (St.
Louis, MO).
Echocardiography. Transthoracic two-dimensional M-mode echocardiogram
and pulsed wave Doppler spectral tracings were obtained using a Sequioa-512
Ultrasound System (Siemens AG, Munich, Germany) with a 15-MHz transducer
in mice anesthetized using a mixture of 1.5% isoﬂurane and 0.5 L/min oxygen.
ColorDopplerwasusedtoshowaccuratelythemitralvalveinﬂowandtoobtain
asharpersignalfromtheearlyventricularﬁllingpeakvelocity(Ewave)andlate
ﬁlling velocity (A wave). M-mode tracings were used to measure left ventricular
(LV) wall thickness, LV end-systolic diameter (LVESD), and LV end-diastolic
diameter (LVEDD). Percentage of fractional shortening was calculated as
described previously (29). All examinations were performed by the same
personnel.
Langendorff perfusion analysis. LV function was measured using isolated
buffer-perfused heart preparation as described previously (28,30). In brief,
isolated hearts were perfused retrograde using normothermic Krebs-Henseleit
buffer (118 mol/L NaCl, 25 mol/L NaHCO3, 4.7 mol/L KCl, 1.2 mol/L KH2PO4,
1.2 mol/L MgSO4, 12 mol/L glucose, and 1.9 mol/L CaCl2) at a constant per-
fusion pressure of 70 mmHg and paced at 7 Hz. The Krebs-Henseleit buffer
was gassed continuously with 95% O2 and 5% CO2. A small polyvinyl chloride
ﬂuid-ﬁlled balloon attached to polyethylene tubing was placed in the LV via the
left atrium and connected to a pressure transducer for determination of LV
pressures. The balloon was progressively ﬁlled in 5-mL increments to generate
LV ﬁlling and functional curves.
Detection of apoptosis by transferase-mediated dUTP nick end–labeling
staining. To estimate apoptosis, terminal deoxynucleotidyl transferase-me-
diated dUTP nick end–labeling (TUNEL) staining, followed by DAPI staining,
was carried out on 4-mm-thick parafﬁn–embedded sections using a cell death
detection assay kit as speciﬁed by the manufacturer’s instructions (Roche
Applied Science, Indianapolis, IN). TUNEL-positive nuclei within the car-
diomyocytes were counted. The total number of nuclei per unit area of the
heart was estimated by counting the number of DAPI-stained nuclei under
ultraviolet illumination. The number of apoptotic cardiomyocyte nuclei in 15
ﬁelds was averaged, and the data were calculated as the percentage of apo-
ptotic myocyte nuclei/total number of nuclei.
Evaluation of autophagic vacuole by electron microscopy. Hearts were
retrograde perfused using PBS and 2% glutaraldehyde in 0.1 mol/L cacodylate
buffer. Postﬁxation was performed using 2% osmium tetroxide in 0.1 mol/L
cacodylate buffer and 1% aqueous uranyl acetate, each for 1 h. Next, the hearts
were conventionally prepared for transmission electron microscopy (31). A
Hitachi H-7600 Transmission Electron Microscope (Pleasanton, CA) equipped
with a digital camera was used to image the sections. Ultrastructural studies
were performed to probe for double membrane-bound autophagic vacuoles,
a long-established analytic gold standard for autophagy. The alternations of
myoﬁbril and mitochondrial ultrastructure were determined from electron
micrographs (original magniﬁcation 34,000).
AMPK activity assay. AMPK activity was measured in ;20 mg of cardiac
tissue, as described previously (10), using the S-adenosylmethionine peptide
as a substrate. AMPK activity was expressed as picomoles of phosphate in-
corporated per milligram of muscle protein subjected to immunoprecipitation
per minute.
Immunohistochemistry and Western analysis. Immunohistochemistry and
Western blots were performed using the speciﬁc antibodies, as described
previously (27,32). The intensities (density 3 area) of individual bands were
measured by densitometry (Model GS-700, Imaging Densitometer; Bio-Rad,
Hercules, CA).
Statistical analysis. Values are presented as mean 6 SEM. Differences be-
tween experimental groups were determined by one-way or two-way ANOVA,
followed by the Bonferroni post hoc test, as appropriate. An unpaired Student
t test was performed for single comparisons between groups. P , 0.05 was
considered statistically signiﬁcant.
RESULTS
Inhibition of AMPKa2 reduces myocardium autoph-
agy, aggravates cardiac dysfunctions, and increases
mortality of diabetic mice. AMPK plays a critical role
in glucose deprivation and ischemia-induced autophagy
in cardiomyocytes (18). To examine the regulatory role
of AMPK in autophagy in the heart, we measured AMPK
activity and LC3-II levels in cardiac tissues collected
from WT and DN-AMPKa2m i c e( 3 3 ) .T h ee x p r e s s i o no f
AMPKa2 was signiﬁcantly increased in DN-AMPKa2t r a n s -
genic mice relative to WT mice; however, the amount
of AMPKa1 was unchanged in the DN-AMPKa2h e a r t s
(Fig. 1A). Overexpression of DN-AMPKa2 reduced AMPKa2
activity but did not affect AMPKa1a c t i v i t y .S T Z - i n d u c e d
diabetes reduced AMPKa1a n dA M P K a2a c t i v i t yi nt h eW T
hearts but not in the DN-AMPKa2 hearts (Fig. 1A). Although
DN-AMPKa2 transgenic mice have a normal cardiac phe-
notype, their hearts exhibited lower LC3-II levels (Fig. 1B),
indicating a reduced autophagy in the hearts from DN-
AMPKa2 transgenic mice.
We next evaluated the effect of reduced autophagy
on the development of diabetic cardiomyopathy in
DN-AMPKa2 transgenic mice, in which AMPK activity is
inhibited (Fig. 1A). STZ was used to render 8-week-old WT
and DN-AMPKa2 diabetic mice. Six months after diabetes
induction, the STZ-injected mice had higher serum glucose
levels than their nondiabetic control subjects (WT: 488 6
25 vs. 119 6 7 mg/dL, P , 0.001, n = 11; DN-AMPKa2:
493 6 27 vs. 129 6 11 mg/dL, P , 0.001, n = 9). Diabetes
reduced LC3-II levels in WT mice but did not further de-
crease LC3-II levels in DN-AMPK mice (Fig. 1C).
LV systolic function was assessed from the maximal LV-
developed pressure, measured over a range of volumes.
LV-developed pressures were depressed in both diabetic
groups after 6 months of diabetes. However, LV-developed
pressures in DN-AMPKa2-STZ mice were lower than those
of WT STZ mice (Fig. 1D). Diabetes increased mortality in
DN-AMPKa2 mice (Fig. 1E), such that only 35.7% survived
at 8 months after STZ induction versus 64.2% in WT mice
with diabetes (P = 0.0581). These ﬁndings suggest that
AMPK deﬁciency in hearts reduced autophagy and cardiac
function in diabetic mice.
Reduction of AMPK activity is associated with
autophagy defection and cardiomyopathy in OVE26
mice. STZ is reported to have direct cardiac toxicity (34).
To exclude the toxic effect of STZ in hearts, we in-
vestigated AMPK activity, autophagy, and cardiac function
in OVE26 mice, an established model of type 1 diabetes. As
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vere hyperglycemia and developed cardiac abnormalities
at 5 to 6 months of age. Of note, neither the transgene nor
diabetes increased the blood pressure in OVE26 mice
compared with FVB mice, whereas the lung wet weight/
dry weight ratio was signiﬁcantly increased (16%) in
OVE26 mice (Table 1), suggesting impaired cardiac per-
formance in the diabetic animals. Moreover, chronic ad-
ministration of metformin diminished diabetes-enhanced
ﬂuid retention in the lung.
To assess the role of autophagy in diabetic cardiomy-
opathy, we measured cardiac LC3-II levels with an LC3-
speciﬁc antibody after 6 months of diabetes. Western blots
revealed a decrease in LC3-II levels in the hearts from
OVE26 mice versus FVB controls. Remarkably, activation
of AMPK with metformin abrogated the reduction of LC3-II
levels in diabetic hearts (Fig. 2A and B). Electron micro-
graphic analysis of ventricular tissue double membrane–
bound autophagic vesicles conﬁrmed the reduction of
autophagy in diabetic hearts. Some autophagosomes could
be identiﬁed in hearts of FVB controls but were rarely
detected in OVE26 mice, suggesting a defect in autophagy.
Chronic administration of metformin prevented the de-
crease in autophagosomes in diabetic hearts (Fig. 2C and
D). To determine the acute effect of metformin on
autophagy, we treated 6-month-old FVB and OVE26 mice
with metformin (200 mg/kg per day) by intraperitoneal
injection. At 24 h after the treatment, metformin increased
TABLE 1
General features of the mice
Variable FVB OVE26 OVE26/metformin
n 10 8 6
Age (month) 6.2 6 0.1 6.1 6 0.1 5.9 6 0.3
Blood glucose (mg/dL) 139.4 6 11.2 420.4 6 22.7* 450.8 6 10.3*
HbA1c (%) 6.2 6 0.4 9.3 6 0.2* 8.7 6 0.3*
Plasma insulin (ng/mL) 2.9 6 0.6 1.2 6 0.3* 1.1 6 0.3*
Body weight (g) 31.0 6 0.3 23.3 6 1.1* 25.5 6 3.1*
Heart weight (mg) 146.5 6 3.3 109.6 6 5.1* 119.1 6 8.9*
Heart weight/body weight (mg/g) 4.8 6 0.1 4.8 6 0.1 4.8 6 0.3
Blood pressure (mmHg) 118.0 6 3.0 116.0 6 6.0 125.0 6 9.0
Lung weight/dry weight ratio (g/g) 4.7 6 0.1 5.3 6 0.1* 4.8 6 0.1†
*P , 0.05 vs. FVB; †P , 0.05 vs. OVE26.
FIG. 1. Inhibition of AMPK by overexpression of DN-AMPKa2 reduces autophagy in transgenic mice, aggravates diabetic cardiomyopathy, and
increases mortality in STZ mice. A: AMPK expression and activity in cardiac tissues from WT and DN-AMPKa2 (DN) transgenic mice treated with/
without STZ were detected as described in RESEARCH DESIGN AND METHODS. ♣P < 0.05 vs. WT control (Con; n =5 –6 in each group). B and C: Western
blot analyses of heart homogenates with anti-LC3 antibody. Densitometric analysis of LC3-II levels is shown by the bar graph. Results shown are
mean 6 SEM. ♣P < 0.05 vs. FVB (n = 4 in each group). D: Langendorff perfusion analysis of the relationship between LV-developed pressure and
volume in WT, DN-AMPKa2 (DN), WT STZ, DN STZ mice 6 months after induction of diabetes. ♣P < 0.05, WT vs. WT STZ, or DN STZ; *P < 0.05, DN
vs. WT STZ or DN STZ; †P < 0.05 DN STZ vs. WT STZ (n =4 –5 in each group). E: Survival plots for WT STZ and DN STZ animals (n = 14 in each
group).
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mice (Fig. 2E). In an in vitro experiment, incubation of
HL-1 cells, a cardiomyocyte-derived cell line (36–38), with
metformin for 16 h increased AMPK phosphorylation and
LC3-II levels (Fig. 2F).
Metformin activates AMPK and improves cardiac
function in OVE26 mice. We further determined whether
chronic activation of AMPK with metformin improved car-
diac function in OVE26 mice. Compared with FVB controls,
AMPK activity was dramatically decreased in OVE26 mice
(Fig. 3A). Consistent with the downregulation in AMPK ac-
tivity, diabetes also reduced AMPK phosphorylation at
threonine 172 (Fig. 3B and C). Metformin treatment pre-
vented the decrease in AMPK phosphorylation and activity
(Fig. 3A–C), alleviated ﬂuid retention in diabetic lungs
(Table 1), and completely restored to normal the cardiac
dysfunction in OVE26 mice (Fig. 4).
Metformin prevents the cardiomyopathy that otherwise
develops in diabetic mice. Autophagy plays an important
role in the heart. Under normal or mild stress conditions, it
degrades and recycles cytoplasmic components and selec-
tively removes damaged mitochondria as a cytoprotective
mechanism (3). We have investigated the relationship
of metformin on cardiac autophagy and the development
of diabetic cardiomyopathy. Echocardiographic analy-
ses demonstrated that OVE26 mice developed severe
cardiomyopathy at 6 months of age, as evidenced by a sig-
niﬁcant increase in LVESD (Fig. 4E) and LVEDD (Fig. 4A)
and a signiﬁcant decrease in ejection fraction (Fig. 4C).
Metformin treatment restored to normal the ejection fraction
FIG. 2. Metformin (Met) restores autophagy in diabetic hearts. A: Immunoblot analysis of heart homogenates using an anti-LC3 antibody.
B: Quantitative analysis of LC3-II levels (n = 6 in each group). ♣P < 0 . 0 5 ,F V Bv s .O V E 2 6 ;†P < 0 . 0 5 ,O V E 2 6 / M e tv s .O V E 2 6 .C: Representative electron
micrographs from cardiac tissues of FVB, OVE26, and metformin-treated OVE26 mice. The arrowheads indicate an autophagic vacuole (original
magniﬁcation of 31,000). D:A u t o p h a g i cv a c u o l e sw e r ec o u n t e df r o mﬁve to six randomly selected ﬁelds. Values represent mean 6 SEM (n =6 ) .♣P <
0.05 vs. FVB; †P < 0.05 vs. OVE26. Note: There were fewer autophagosomes in OVE26 mice. E: FVB and OVE26 mice were injected with metformin (200
mg/kg per day i.p.) for 24 h, and AMPK phosphorylation and LC3-II levels were detected by Western blotting and quantiﬁed to FVB control (Con). ♣P <
0.05 vs. FVB Con; †P < 0.05 vs. FVB Met; #P < 0.05 vs. OVE26 Con (n = 6 in each group). F: Western analyses of phosphorylation of AMPK and LC3-II
levels in HL-1 cells treated with metformin (2 mmol/L) for 24 h. (A high-quality digital representation of this ﬁgure is available in the online issue.)
FIG. 3. Metformin (Met) increases the phosphorylation and activity of AMPK in diabetic hearts. A: AMPK activity in cardiac tissues from FVB,
OVE26 mice, and metformin-treated OVE26 mice was detected as described in RESEARCH DESIGN AND METHODS. ♣P < 0.05 vs. FVB; †P < 0.05 vs. OVE26
(n =5 –6 in each group). B: Representative blots of phosphorylation of AMPK at threonine 172 and total AMPK. C: Densitometric analysis of
expression of phospho-AMPK and total AMPK. ♣P < 0.05 vs. FVB; †P < 0.05 vs. OVE26 (n =5 –6 in each group).
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mice. Fractional shortening, an estimate of cardiac systolic
function, was signiﬁcantly decreased in OVE26 mice (37 6 4
vs. 48 6 4% in FVB mice; Fig. 4D). Metformin therapy
completely corrected the impairment in fractional shortening
in OVE26 mice (Fig. 4D). To assess LV diastolic function, we
measured Doppler ﬂow velocities across the mitral valves
during the diastolic phase. The E/A velocity ratio, an esti-
mate of LV diastolic function, was signiﬁcantly decreased in
OVE26 mice, whereas metformin treatment prevented the LV
diastolic dysfunctions (Fig. 4B and F).
Langendorff perfusion analyses corroborated the car-
dioprotection by metformin in diabetic mice. LV systolic
and diastolic functions were assessed from the maximal
LV-developed pressure, the calculated dp/dtmax (maximal
change in pressure per unit time), and the dp/dt minimum
(dp/dtmin). OVE26 mice exhibited a signiﬁcant reduction in
LV-developed pressure (Fig. 4G) and dp/dtmax (Fig. 4H).
Chronic metformin treatment restored to normal LV-
developed pressure and dp/dtmax (Fig. 4G and H). The
dp/dtmin measurement is generally considered to reﬂect
LV diastolic function, which is impaired in OVE26 mice,
whereas metformin treatment restored cardiac diastolic
function (Fig. 4I).
Overexpression of DN-AMPK abolishes the protective
effects of metformin. To evaluate role of AMPK in
cardioprotection of metformin, WT and DN-AMPKa2d i -
abetic mice were treated with metformin for 4 months
after diabetes induction. Neither STZ nor metformin af-
fected AMPK expression. Metformin treatment enhanced
AMPK activity in WT STZ mice but not in DN STZ mice
(Fig. 5A). Chronic treatment with metformin improved
cardiac function in STZ-induced diabetic WT mice;
however, the salutary effects of metformin on cardiac
function were abrogated in DN-AMPKa2-STZ mice (Fig.
5B). In addition, metformin reduced mortality in WT STZ
mice, and this effect was prevented in DN STZ mice (Fig.
5C). These results suggest that activation of AMPK is
essential for metformin to impart its cardioprotection in
diabetes.
FIG. 4. Metformin (Met) prevents cardiac dysfunction in diabetic mice. A–F: Echocardiographic assessment of cardiac function as described in
RESEARCH DESIGN AND METHODS. All measurements were determined in a short-axis view at the level of the papillary muscles. Representative images of
M-mode echocardiography (A) and mitral valvular inﬂows show E wave and A wave (B). C: Ejection fraction. D: Percentage of fractional shortage
as LV contractile function. E: LV end-systolic diameter. F: Diastolic ﬁlling as assessed by E/A ratio (E wave: LV early-ﬁlling wave; A wave: ﬁlling
from atrial contraction). Values represent mean 6 SEM. FVB,n= 11; OVE26,n= 8; metformin-treated OVE26,n=6 .♣P < 0.05 vs. FVB; †P < 0.05
vs. OVE26. G: Analysis of LV-developed pressure vs. volume. The developed pressure was depressed in OVE26 mice, which was prevented by
metformin. Metformin improved LV dp/dtmax (H) and dp/dtmin (I) in OVE26 mice. Results shown are mean 6 SEM. ♣P < 0.05 vs. OVE26. FVB, n =6 ;
OVE26, n = 5; metformin-treated OVE26 mice, n = 5. (A high-quality color representation of this ﬁgure is available in the online issue.)
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levels in diabetic hearts. Beclin1 has a key role in
autophagy because it is involved in the formation of
autophagosomes (39). Beclin1 expression is increased in
hibernating myocardium (40) and during reperfusion,
where increased autophagy was documented (18). To ex-
amine the role of Beclin1 in diabetic cardiomyopathy, we
measured and found reduced Beclin1 protein expression
in hearts of OVE26 mice at age 6 months (Fig. 6A and B).
It is noteworthy that metformin dramatically enhanced
Beclin1 protein expression in OVE26 mice (Fig. 6A and B).
Metformin inhibits tuberous sclerosis complex-mTOR
pathway in diabetic hearts. Previous studies suggest
that AMPK negatively regulates mTOR activity (41) and
plays an important role in mediating starvation-induced
autophagy (42). Thus, we examined whether metformin
inhibits the tuberous sclerosis complex (TSC)-mTOR
pathway. Diabetic hearts exhibited activated TSC-mTOR
FIG. 5. Metformin (Met) improves cardiac function and survival rate in an AMPK-dependent manner. A: AMPK expression and activity in cardiac
tissues from the animals were detected as described in RESEARCH DESIGN AND METHODS. ♣P < 0.05 vs. WT STZ control (Con), †P < 0.05 vs. WT STZ Met
(n =5 –6 in each group). B: Langendorff perfusion analysis of the relationship between LV-developed pressure and volume in WT STZ, DN STZ, WT
STZ Met, and DN STZ Met mice 6 months after induction of diabetes. ♣P < 0.05, WT STZ Met vs. WT STZ, DN STZ Met, or DN STZ; †P < 0.05 DN
STZ vs. WT STZ (n =4 –5 in each group). C: Survival plots for WT STZ, DN STZ, WT STZ Met, and DN STZ Met animals (n =1 4 –16 in each group).
FIG. 6. Metformin (Met) increases the expression of Beclin1 and inhibits mTOR signaling in the heart. A: Immunohistochemical analysis of Beclin1
in the hearts from FVB, OVE26, and metformin-treated OVE26 mice. Nonspeciﬁc rabbit IgG was used as a negative control. B: Quantitative analysis
of Beclin1-stained areas is shown by the bar graph. Results shown are mean 6 SEM. ♣P < 0.05 vs. FVB; †P < 0.05 vs. OVE26 (n = 4 in each group).
C: Western analysis of the mTOR signaling pathway in cardiac tissues from FVB, OVE26, and metformin-treated OVE26 mice. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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lation of Raptor at both Ser722 and Ser792, as well as in-
creased phosphorylation of mTOR at both Ser2448 and
Thr2446 and its downstream effectors, including 4E-bind-
ing protein 1 (4EBP1) and p70 ribosomal protein S6 kinase
1 (p70 S6K1). Activation of AMPK by metformin paralleled
the inhibition of TSC-mTOR signaling (Fig. 6C).
Metformin ameliorates ultrastructural abnormalities
in diabetic hearts. Morphology of LV tissues from FVB,
OVE26, and metformin-treated OVE26 mice were analyzed
by transmission electron microscopy (Fig. 7). Cardio-
myocytes from control FVB mice (Fig. 7A) exhibited nor-
mal myocardial ﬁne structure, with myoﬁbrils composed
of regular and continuous sarcomeres, and mitochondria
formed longitudinal rows between myoﬁbrils. In contrast,
heart tissues from OVE26 mice (Fig. 7B) showed the ad-
verse effects of diabetes, as exempliﬁed by the misalignment
and aggregation of mitochondria randomly interspersed
between disrupted myoﬁbrils. These distorted and chaotic
architectures suggest defects in autophagy, the primary
mechanism of mitochondrial turnover during normal de-
velopment and pathologic conditions. Chronic metformin
conferred striking protective effects against myocardial
injuries inﬂicted by diabetes (Fig. 7C). There was no de-
tectable difference in the ﬁne structure of mitochondria
and myoﬁbrils between mouse hearts from nondiabetic
controls and metformin-treated OVE26 mice.
Metformin attenuates the upregulation of ubiquiti-
nated protein and apoptosis in diabetic hearts. Sup-
pression of autophagy could cause abnormal proteins to
accumulate and promote apoptosis. To test this concept in
our model, we probed ubiquitin in the cardiac homoge-
nates from FVB, OVE26, and metformin-treated OVE26
mice. We found that polyubiquitinated protein levels were
increased in OVE26 mouse hearts. This increase was pre-
vented by metformin administration (Fig. 8A and B).
TUNEL staining revealed more apoptotic cells in OVE26
mouse hearts compared with the FVB. Metformin treat-
ment, however, reduced the number of apoptotic cells in
diabetic hearts (Fig. 8C).
DISCUSSION
The cardioprotective effects of metformin have been con-
sidered related to its beneﬁcial actions on lipid metabolism,
endothelial function, calcium homeostasis, hypercoagula-
tion, and platelet reactivity (7). In the present investigation,
we identiﬁed a new mechanism by which metformin pre-
vents the development of diabetic cardiomyopathy. Our
ﬁndings demonstrate that inhibition of AMPK by the over-
expression of a cardiac-speciﬁc DN-AMPK gene inhibits
cardiomyocyte autophagy, exacerbates cardiac dysfunc-
tion, and increases mortality in diabetic mice. Diabetes
reduces AMPK activity and cardiomyocyte autophagy,
resulting in the accumulation of clustered and damaged
mitochondria and polyubiquitinated protein, associated
with signiﬁcantly impaired cardiac functions. More im-
portant, chronic activation of AMPK by metformin signiﬁ-
cantly enhances autophagic activity and prevents diabetic
cardiomyopathy in diabetic mice. The cardioprotective
effect of metformin is abolished in STZ-induced diabetic
mice overexpressing DN-AMPK. These studies implicate
inhibition of cardiac autophagy in the pathogenesis of di-
abetic cardiomyopathy and suggest that metformin confers
cardiac protection, at least in part, by stimulating AMPK
activity and consequently increasing autophagic activities.
The major ﬁnding in this study is that metformin
enhances cardiac autophagic activities in diabetic mice,
which may prevent the development of diabetic cardio-
myopathy. Autophagy is essential in cell growth, de-
velopment, and homeostasis, where it maintains a balance
between the synthesis, degradation, and subsequent recy-
cling of cellular components. It allows recycling of amino
acids and removal of damaged organelles to eliminate
oxidative stress and promote remodeling for survival
(43,44). A low level of constitutive autophagy is cytopro-
tective by maintaining the quality of proteins and organ-
elles and cell functions in the heart (4). Hartley et al. (45)
have demonstrated that chronic hyperglycemia induces
aggregation of ubiquitinated proteins in a pancreatic b-cell
line. Treatment of pancreatic b-cells with 3-methyladenine,
an inhibitor of autophagy, induces the aggregates of
ubiquitinated proteins. These observations suggest that
autophagy normally removes the misfolded or aggregated
proteins induced by diabetes to defend against diabetes-
induced cellular damage (45).
In the current study, we demonstrated inhibition of car-
diac autophagy by diabetes, as evidenced by fewer auto-
phagosomes, lower LC3-II protein levels, and decreased
Beclin-1 protein expression. As a result, polyubiquitinated
protein levels were increased in diabetic hearts, which
displayed a disorganized sarcomere structure, misalign-
ment, and aggregation of mitochondria, demonstrating the
importance of autophagy in organelles turnover. The ac-
cumulation of ubiquitinated proteins is known to induce
endoplasmic reticulum stress and apoptosis in cardiomyo-
cytes. Moreover, damaged mitochondria release reactive
oxygen species (46) and proapoptotic factors such as cy-
tochrome c (2) to trigger apoptosis. Thus, accumulation of
abnormal proteins and damaged organelles, such as mito-
chondria, could directly result in cardiac dysfunction.
However, the current study has not established a conclusive
link between enhanced autophagy and improved cardiac
function in metformin-treated diabetic hearts. Although
chronic metformin therapy signiﬁcantly enhanced auto-
phagic activity and preserved cardiac functions in OVE26
mouse hearts, the changes in autophagy and myocardial
function in diabetes, with or without metformin treatment,
are still correlative. Further investigation is warranted.
Our observations provide direct experimental support
for a protective role of AMPK activation in diabetic
FIG. 7. Metformin (Met) protects cardiac ultrastructure from chronic
diabetic damage. Representative transmission electron micrographs of
cardiac tissues from LVs are shown from FVB mice (A), OVE26 mice (B),
a n dO V E 2 6m i c et r e a t e dw i t hm e t f o r m i n( C). A and C:F V Ba n dm e t f o r m i n -
treated OVE26 animals show normal myocardial structure, with myoﬁbrils
comprised of regular and continuous sarcomeres. Rows of moderately
electron dense mitochondria (M) intervene between myoﬁbrils. B:O V E 2 6
diabetic myocardium shows randomly distributed mitochondria (M) be-
tween poorly organized myoﬁbrils (original magniﬁcation of 34,000;
n =6 –7 in each group). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
METFORMIN ATTENUATES DIABETIC CARDIOMYOPATHY
1776 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgcardiomyopathy. First, AMPK activity and phosphorylation
on Thr172 were both apparently reduced in diabetic
hearts, accompanied by impaired cardiac structure and
function. Second, chronic metformin increased AMPK
activity and prevented the structural and functional
derangements in diabetic cardiomyopathy. Third, myo-
cardial AMPKa2 inhibition was associated with worsened
cardiac dysfunctions and increased mortality in diabetic
mice. Finally, the cardioprotective actions of metformin
were abolished in the mice deﬁcient of AMPKa2. These
ﬁndings suggest that activation of AMPK is required for
metformin to confer its cardioprotective actions in the
diabetic cardiomyopathy.
To our knowledge, this is the ﬁrst report of a decrease in
AMPK activity in the heart from diabetic rodents. AMPK
has emerged as a key regulator of cellular energy ho-
meostasis in the heart, and inactivation of AMPK would
impair energy metabolism and cardiac function. Chronic
metformin therapy restores cardiac AMPK activity and
improves cardiac function in diabetic OVE26 mice, sup-
porting that dysregulation of AMPK is an important event
in the pathogenesis of diabetic cardiomyopathy.
Elucidating the mechanism responsible for the decreased
AMPK activity in the diabetic heart may open a new horizon
for the treatment and prevention of diabetic cardiomy-
opathy. Several studies have provided evidence linking the
AMPK signaling pathway to autophagy. Compound C,
a speciﬁc AMPK inhibitor (47) or a DN form of AMPK,
inhibits starvation-induced autophagy in various mam-
malian cells (48). Glucose deprivation induces autophagy
via activation of AMPK and inhibition of mTOR in iso-
lated cardiomyocytes (18), whereas autophagy induced
by myocardial ischemia is suppressed in transgenic mice
overexpressing a DN-AMPK (18). In the current study, we
have demonstrated that decreased cardiac AMPK activity
is associated with lower Beclin1 levels and defective
autophagy, whereas metformin restores Beclin1 expres-
sion and autophagic activity. Moreover, diabetes reduces
phosphorylation of Raptor, increases phosphorylation
of mTOR, and activates the mTOR downstream effectors
4EBP1 and p70S6K1, all of which indicate activation of
TSC-mTOR signaling. Activation of AMPK by metformin
inhibits the TSC-mTOR pathway and restores cardiac
autophagy in OVE26 mice. Collectively, metformin-activated
AMPK stimulates autophagic activities in cardiomyocytes by
modulating Beclin1 and the TSC-mTOR pathway.
In summary, our ﬁndings demonstrate that decreased
AMPK activity and the subsequent reduction in cardiac
autophagy are central to the development of diabetic
cardiomyopathy. Metformin prevents diabetic cardiomy-
opathy by stimulating AMPK activity and enhancing auto-
phagic capacity. Thus, stimulation of AMPK may represent
a novel approach to treat diabetic cardiomyopathy.
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